These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 1377119)

  • 21. [Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes].
    Barrelet L; Blajev B; Bolzani L; de Saussure C; Kasas A; Van H; Gachoud JP
    Schweiz Rundsch Med Prax; 1991 May; 80(19):524-8. PubMed ID: 1904620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
    Korn A; Eichler HG; Fischbach R; Gasic S
    Psychopharmacology (Berl); 1986; 88(2):153-7. PubMed ID: 3081926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of a reversible monoamine oxidase-A inhibitor versus imipramine in subgroups of depressed patients.
    Bizière K; Berger M
    Acta Psychiatr Scand Suppl; 1990; 360():59-60. PubMed ID: 2248074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New pharmacological approaches to the management of depression: from theory to clinical practice.
    Norman TR; Judd FK; Burrows GD
    Aust N Z J Psychiatry; 1992 Mar; 26(1):73-81. PubMed ID: 1580888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressants, alcohol and psychomotor performance.
    Tiller JW
    Acta Psychiatr Scand Suppl; 1990; 360():13-7. PubMed ID: 2248062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moclobemide: a paradigm of research in clinical psychopharmacology.
    Angst J; Amrein R; Stabl M
    Int Clin Psychopharmacol; 1996 Jun; 11 Suppl 3():3-7. PubMed ID: 8923103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.
    Dechant KL; Clissold SP
    Drugs; 1991 Feb; 41(2):225-53. PubMed ID: 1709852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
    Tiller JW; Maguire KP; Davies BM
    Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP; Tsoi WF
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression.
    Paykel ES
    Acta Psychiatr Scand Suppl; 1995; 386():22-7. PubMed ID: 7717091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder.
    Laux G; Beckmann H; Classen W; Becker T
    J Neural Transm Suppl; 1989; 28():45-52. PubMed ID: 2677241
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moclobemide (Ro 11-1163) safety in depressed patients.
    Moll E; Hetzel W
    Acta Psychiatr Scand Suppl; 1990; 360():69-70. PubMed ID: 2248078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical overview on moclobemide.
    Tiller JW
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Sep; 17(5):703-12. PubMed ID: 8255982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial.
    Guelfi JD; Payan C; Fermanian J; Pedarriosse AM; Manfredi R
    Br J Psychiatry; 1992 Apr; 160():519-24. PubMed ID: 1571752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders.
    Newburn GM; Fraser AR; Menkes DB; Mullen PE
    Aust N Z J Psychiatry; 1990 Dec; 24(4):475-9. PubMed ID: 2073222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Moclobemide].
    Gleiter C; Volz HP
    Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1175-6. PubMed ID: 7656852
    [No Abstract]   [Full Text] [Related]  

  • 39. Multicenter double-blind study of moclobemide and maprotiline.
    Vaz-Serra A; Figueira ML; Firmino H; Albuquerque AJ; Jara JM; Pestana LC
    Clin Neuropharmacol; 1994; 17 Suppl 1():S38-49. PubMed ID: 7954483
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.